Wells Fargo’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q4
Sell
-322
Closed -$6.32K 7590
2023
Q3
$6.32K Buy
+322
New +$7.15K ﹤0.01% 5920
2022
Q2
Sell
-225
Closed -$6K 6792
2022
Q1
$6K Hold
225
﹤0.01% 6412
2021
Q4
$9K Hold
225
﹤0.01% 6568
2021
Q3
$10K Hold
225
﹤0.01% 6194
2021
Q2
$11K Sell
225
-154
-41% -$7.54K ﹤0.01% 6105
2021
Q1
$19K Sell
379
-691
-65% -$37.8K ﹤0.01% 6166
2020
Q4
$53K Hold
1,070
﹤0.01% 5567
2020
Q3
$42K Buy
1,070
+845
+376% +$34.4K ﹤0.01% 5571
2020
Q2
$10K Hold
225
﹤0.01% 5840
2020
Q1
$7K Hold
225
﹤0.01% 5797
2019
Q4
$9K Hold
225
﹤0.01% 5911
2019
Q3
$5K Sell
225
-729
-76% -$19.8K ﹤0.01% 6053
2019
Q2
$27K Sell
954
-25
-3% -$698 ﹤0.01% 5724
2019
Q1
$27K Buy
979
+25
+3% +$655 ﹤0.01% 5451
2018
Q4
$22K Buy
954
+225
+31% +$6.14K ﹤0.01% 5756
2018
Q3
$25K Hold
729
﹤0.01% 5771
2018
Q2
$24K Hold
729
﹤0.01% 5778
2018
Q1
$24K Hold
729
﹤0.01% 5765
2017
Q4
$21K Hold
729
﹤0.01% 5784
2017
Q3
$21K Hold
729
﹤0.01% 5697
2017
Q2
$18K Hold
729
﹤0.01% 5646
2017
Q1
$17K Hold
729
﹤0.01% 5744
2016
Q4
$13K Buy
+729
New +$14.5K ﹤0.01% 5728

Other funds holding BBC

Wells Fargo's BBC Position: Q4 2023 in Review

Wells Fargo sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2023, closing a stake of 322 shares — an estimated $6.32K sold.

Wells Fargo first reported a position in BBC in Q4 2016 and held it in 23 quarters. The position peaked at $53K in Q4 2020. 18 funds tracked by Wall St. Rank hold BBC as of Q4 2023.

  • Wells Fargo reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2023 after selling out during the quarter.
  • Wells Fargo sold 322 Virtus Biotech Clinical Trials ETF shares in Q4 2023, an estimated $6.32K.
  • Wells Fargo first reported a position in Virtus Biotech Clinical Trials ETF in Q4 2016 and held it in 23 quarters.
  • Wells Fargo's Virtus Biotech Clinical Trials ETF position peaked at $53K in Q4 2020.
  • 18 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2023.

Based on Wells Fargo's 13F filing for Q4 2023, filed 9 Feb 2024.